| Revenue guidance | 20.0% → 40.0% Raised by 20.0 percentage points |
|---|---|
| Management target | Revenue 30.0% FY28 |
| Revenue growth | Guided 25-30% YoY growth through FY30. |
|---|---|
| Margins | EBITDA margins expected to reach 30% as revenue hits ₹1,000Cr. |
| Demand visibility | Strong visibility from distributors in LATAM and MENA markets. |
| Management confidence | High; visibility from 60-70 new registrations and expansion plans. |
Growth
FY27 revenue guidance revised to ₹700Cr+ from ₹600Cr, implying 40% growth YoY; oncology currently contributes 20-25% of revenue.
Outlook
Targeting ₹1,500Cr revenue by FY30. ₹190Cr capex planned for hormone, oncology, and biosimilars; KPMG to be appointed auditor by Q4FY27.
Risks
Potential delays in international registrations and clinical trial timelines for biosimilars; elevated debtor days at 165-170 days.
Last quarter's promises, checked
Delivered
- Guided FY26 Revenue ₹500Cr+ → delivered ₹503Cr (= BEAT)
- Guided FY27 Revenue ₹650Cr → delivered ₹700Cr+ (= BEAT)
- Guided FY26 EBITDA Margin 22% → delivered 24% (= BEAT)
Partly delivered
- Guided Cash Conversion Cycle 208 days → delivered 170 days (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,688.55
- Market cap
- ₹3,827 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.2×Sector 47.4×
- Promoter holding
- 54.86%-0.01% QoQ
- FII holding
- 3.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Kwality Pharmaceuticals Q1 FY27 Results: Net Profit ₹25.6 Cr, Up 115.1% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹25.6 Cr · +115.1% YoY
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Limited has announced the closure of its share transfer books from August 25, 2026, to August 31, 2026, for its 43rd Annual General Meeting.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited has announced its 43rd Annual General Meeting, scheduled to be held on August 31, 2026, through video conferencing.